About
ADARx Pharmaceuticals, Inc.
ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases.
The company offers hepatic-targeted programs, including Agazisiran, a complement factor B (CFB) program that represents a pipeline-in-a-product opportunity, where a single therapeutic candidate has the potential to address multiple indications; Onvuzosiran, a clinical program for the prevention of HAE attacks; and ADX-626, a Factor XI (FXI) program for secondary stroke prevention with additional clinical potential for stroke prevention in atrial fibrillation.
It also offers extrahepatic-targeted programs, such as ADX-077, an adipose-targeted obesity program designed to reduce body weight and fat while preserving lean mass; and ADX-199, a neuron-targeted program designed to selectively silence and degrade amyloid-ß precursor protein (APP) mRNA in neurons, which is genetically linked to Alzheimer’s disease.
ADARx Pharmaceuticals, Inc. Overview
Ticker, listing venue and issuer profile
Offer & Key Dates
Pricing terms and IPO milestones
Change from offer price to today
Live Market Snapshot
Real-time price; headline % change is vs first trade (listing price)
USD · NASDAQ:NASDAQ:ADRX
Valuation & Multiples
Key valuation ratios and metrics
Financial Health
Balance sheet strength and liquidity
Financial Highlights
Historical financial performance
Historical Data
Market history and supplemental quote data
| Date | Open | High | Low | Close | Adj. Close | Change | Volume |
|---|---|---|---|---|---|---|---|
| 2026-09-29 | $19.90 | $21.50 | $19.51 | $20.64 | $20.64 | +0.74 | 1,299,400 |
| 2026-09-28 | $19.00 | $21.77 | $18.50 | $20.09 | $20.09 | +1.09 | 1,205,200 |
| 2026-09-25 | $22.10 | $23.21 | $19.00 | $19.35 | $19.35 | -2.75 | 4,213,100 |
SEC Filings
Official documents from SEC EDGAR
| Form | Filing Date | Document |
|---|---|---|
| S-8 | Sep 28, 2026 | Securities to be offered to employees in employee benefit plans |
| 8-K | Sep 28, 2026 | Current Report |
| 424B4 | Sep 28, 2026 | Prospectus |
| EFFECT | Sep 24, 2026 | Notice of Effectiveness |
| S-1MEF | Sep 24, 2026 | Registration adding securities to prior Form S-1 registration |
| CERT | Sep 24, 2026 | Certification by an exchange approving securities for listing |
| 8-A12B | Sep 22, 2026 | Registration of securities |
| S-1/A | Sep 21, 2026 | [Amend] General form for registration of securities under the Securities Act of 1933 |
| S-1/A | Sep 14, 2026 | [Amend] General form for registration of securities under the Securities Act of 1933 |
| S-1 | Sep 4, 2026 | General form for registration of securities under the Securities Act of 1933 |
Company Info
Contact and headquarters details
Leadership
Key executives and officers
Zhen Li, Ph.D.
President, Chief Executive Officer and Director
Ryan Fisk, M.B.A.
Chief Financial Officer and Chief Business Officer
A. Robert MacLeod, Ph.D.
Chief Scientific Officer
Rui Zhu, Ph.D.
Chief Technology Officer
Robert Ackles
Chief People Officer
Erez Chimovits, M.B.A.
Interim Chairman
Ting Feng, Ph.D.
Director
Simeon George, M.D., M.B.A.
Director
Carl L. Gordon, Ph.D., CFA
Director
Ying Huang, Ph.D.
Director
